Innate Pharma S.A.
IPH.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | €129,772 | €117,586 | €120,633 | €159,625 |
| - Cash | €53,704 | €66,396 | €69,990 | €70,605 |
| + Debt | €27,029 | €30,995 | €35,503 | €39,893 |
| Enterprise Value | €103,097 | €82,185 | €86,146 | €128,913 |
| Revenue | €4,860 | €7,776 | €12,345 | €21,443 |
| % Growth | -37.5% | -37% | -42.4% | – |
| Gross Profit | -€15,660 | -€15,128 | -€16,731 | -€3,126 |
| % Margin | -322.2% | -194.5% | -135.5% | -14.6% |
| EBITDA | -€25,061 | -€23,053 | -€25,563 | -€10,396 |
| % Margin | -515.7% | -296.5% | -207.1% | -48.5% |
| Net Income | -€21,344 | -€24,707 | -€24,764 | -€9,288 |
| % Margin | -439.2% | -317.7% | -200.6% | -43.3% |
| EPS Diluted | -0.25 | -0.3 | -0.31 | -0.11 |
| % Growth | 16.7% | 3.2% | -181.8% | – |
| Operating Cash Flow | -€31,164 | -€9,932 | €3,036 | -€21,093 |
| Capital Expenditures | -€58 | -€108 | -€283 | -€42 |
| Free Cash Flow | -€31,222 | -€10,040 | €2,753 | -€21,135 |